Drugs / NC762
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04875806 | Jun 2021 → Jan 2024 | breast cancer, non-small cell lung carcinoma, ovarian carcinoma | NextCure, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NC762 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04875806 ↗ |
| Modality | Monoclonal antibody | “NC762 is an experimental antibody drug” NCT04875806 ↗ |
| Route | Intravenous | “Subjects received NC762 IV at 0.5mg/kg” NCT04875806 ↗ |